Saturday, 25 August 2018

"Knowledge of drug diffusion mechanisms into the tissue and cellular cytoplasm following bladder
instillation is a key to understand the safety profile and clinical activity of chemotherapy."

Intravesical Chemotherapy and Chemohypherthermia in Non-Muscle-Invasive Bladder
Cancer; An Overview on Drug Administration Technologies and Pharmacokinetics
Campodonico F, Di Stasi S, Lev GM, Terrone C, Bongiovanni L, Mattioli F, Pagliarulo V and Introini C
Current Drug Metabolism, 2017

Despite the widely adopted international guidelines’ recommendations, and recent clinical trials of device-assisted chemotherapy instillations showing markedly enhanced recurrence-free survival compared even to the standard of care, clinicians and pharmacologists are not familiar with the in-depth physical aspects, pharmacokinetics and systemic absorption of chemotherapeutic drugs following their intravesical
administration. This paper gives a comprehensive review covering various aspects of different treatments with intravesical drugs.
Device-assisted therapies have set a goal to potentiate the drug’s effect and efficacy. The Radiofrequency-Induced Thermochemotherapeutic Effect (RITE) and the Electromotive-Drug Administration (EMDA) are the two most relevant modalities used to increase the activity of intravesical chemotherapy.

This new published study examined whether RF-CHT (using Synergo system) results in higher MMC drug tissue concentrations as compared to cold MMC instillation.

Intravesical radiofrequency induced hyperthermia enhances mitomycin C accumulation in tumour tissue,
F. Johannes P. van Valenberg, Antoine G. van der Heijden, Rianne J. M. Lammers, Johannes Falke, Tom J. H. Arends, Egbert Oosterwijk & J. Alfred Witjes
International Journal of Hyperthermia

Patients received either (1) cold drug instillation (Mitomycin) or (2) RF-CHT (Synergo) before a planned transurethral resection operation. After instillation, three biopsy tests were taken of both normal and tumour tissue. The results showed that the median drug concentration in tumour tissue was higher in the RF-CHT (Synergo) group (median 665.00ng/g vs. 63.75ng/g, U¼51.0, p¼0.018). Moreover, in both techniques the MMC concentration was lower in normal tissue compared to tumour tissue. They concluded that Intravesical RF-CHT results in higher tumour MMC concentrations vs. cold MMC instillation which contributes to its superior efficacy.

virtual London (EAU 2017)
Enjoyed meeting all urology specialists at the last EAU conference!

Thursday, 8 June 2017

Updates from the European Association of Urology Guidelines 2017

Bladder Cancer - Updates from the European Association of Urology Guidelines:

The Synergo® treatment has become a common practice in leading centers both as a prophylactic treatment (after TUR) and ablative treatment (for tumour eradication). The prophylactic induction phase includes 6 weekly sessions followed by 6 in a maintenance phase, once every 6 weeks. The clinical outcomes of this adjuvant protocol were recently included in the European Association of Urology Guidelines. A multinational randomised controlled trial comparing the efficacy and safety of Synergo® vs. BCG, presents better results in the Synergo® group (Disease free patients: 81.8% vs. 64.8% respectively in 2-yr follow-up). 

With the new recommendations, Synergo®’s level of evidence makes it the only non-experimental device for the treatment of NMIBC.
The following is taken from the EAU 2017 guidelines:


7.3.3.Treatment of BCG failure and recurrences after BCG

Treatment recommendations are provided in Sections 7.5 and 7.7. They reflect the categories mentioned in Table 7.2 and tumour characteristics at the time of recurrence.
Patients with BCG failure are unlikely to respond to further BCG therapy; RC is therefore the preferred option. Various studies suggest that repeat BCG therapy is appropriate for non-high-grade and even for some high-grade recurrent tumours [232,233] (LE: 3). Additionally, there are now several bladder preservation strategies available that can be categorised as intravesical immunotherapy [234], intravesical chemotherapy, device-assisted therapy (see Section, and combination therapy (see Section 7.2.3) [235]. Changing from BCG to these options can yield responses in selected cases with BCG treatment failure [232,234-242] (LE: 3).
Treatments other than RC must be considered oncologically inferior in patients with BCG failure at the present time [150,229,230] (LE: 3).
Little is known about the optimal treatment in patients with high-risk tumours who could not complete BCG instillations because of intolerance.
Non-high-grade recurrence after BCG is not considered as BCG failure. Treatment decision should be individualised according to tumour characteristics. It could include chemotherapy or repeat BCG instillations, but the published evidence is very low.
Synergo® Technology
The Synergo® device delivers radiofrequency local radiation: a synergistic tri-modality of local, non-ionising Radiofrequency, RF, a chemotherapy instillation, and tissue hyperthermia – all in one, powerful combination, for treating intermediate and high risk Non-Muscle Invasive Bladder Cancer. A special catheter, carrying an embedded small radio-frequency (RF 915 MHz) antenna and thermocouples (special temperature measuring sensors), is introduced into the urinary bladder.
The distal end of the catheter is connected to the Synergo® computer-embedded device that enables the physician to monitor and control the system activity in real-time.
The antenna controllably radiates the bladder walls, while the thermocouples monitor the bladder wall temperature to help ensure that it is kept at a safe range. Chemotherapeutic agent is instilled through the same catheter and constantly circulated and cooled by the heat exchanger unit of the Synergo® device.
Selective effects of RF on cancer cells include phenotypical changes, the formation of micropores on their membranes, and the loss of adhesion between malignant cells – an influential parameter of tumour growth. The drug can now easily penetrate into, and in between these cells, reaching deeper hidden locations. Studies reveal that with RF, even the more resistant cancer cells, become susceptible to chemotherapy, whereas, the effects of RF are negligible on healthy cells. Tissue heating, hyperthermia, is a welcomed by-product of RF. It causes changes in blood perfusion and ruptures in blood supply to malignant cells, as well as unfolding and denaturing of proteins, causing irreparable damages to the DNA selectively in cancer cells. Temperatures of approximately 42 degrees Centigrade, 107 Fahrenheit, are monitored and maintained throughout the treatment.
Temperature elevation of the bladder walls to 42±2ºC enhances the effectiveness of chemotherapeutic agents through several mechanisms additional to those identified in-vitro, including improved tissue penetration and altered immunological response.

May 2017 was bladder cancer awareness month!
Bladder cancer is the fifth most common cancer in the Western world and the second most frequent malignancy of the urinary tract after prostate cancer.

Thursday, 28 July 2016

Recurrence Free Survival at 1, 2 and 5 years was 89.6%, 79.2 and 68.3 respectively

We were thrilled and excited to come across this newly presented Synergo® data at the last Auro National Congress. Dr. Canepa, Dr. Campodonico and team presented their long term outcomes of treatment in Genova centres, Italy.


G. Canepa1, F. Campodonico1, S. Tamagno1, C. Introini2, M. Puntoni3
1 E.O. Ospedali Galliera, S.C. Urologia (Genova) 2 Ospedale Evangelico Internazionale, S.C. Urologia (Genova Voltri) 3 E.O. Ospedali Galliera, Direzione Scientifica e Biostatistica (Genova)

Aim of the study: evaluate the long-term experience on a treatment combining intravesical hyperthermia with Mytomicin C (HT-MMC) delivered with the Synergo® device.
More than 1600 treatments performed since 2004
146 Intermediate and High-risk NMIBC patients
37/146 patients reported a recurrence and 14/146 patients presented a progression.
The Recurrence Free Survival at 1, 2 and 5 years was 89.6%, 79.2 and 68.3 respectively.
Progression Free Survival at 1, 2 and 5 years was 98%, 96.2 and 83.7 respectively.
The number of treatment sessions for each patients were 10.4+/- 4.7 with a median of 11 sessions (Range 4-31). The time of exposure over 42°C was 37.4+/-7.4 mins. and the mean temperature was 42.0+/-0.8°C. The safety profile showed mainly grade 1 and 2 side effects. Ten patients complained grade 3 side-effects, including 1 patient bladder spasms/pain during treatment, 3 patients dysuria and 6 patients urgency after treatment.
Presented at: XXIII Congresso Nazionale Auro May 2016

Wednesday, 17 February 2016

Basic Science Behind NMIBC and its Treatment

The established “two-pathway” model of bladder cancer suggests epithelial hyperplasia and recruitment of branching vasculature as the pathway for the development of papillary NMIBC.
The healthy urothelium is about 60 μm thick. The increase in the epithelial thickness in malignancy reflects the increase in cell dimensions in basal and intermediate layers.

Tumours originating from basal cells were shown to be associated with the worst outcome. Invasive carcinomas arise clonally from a single cell progeny, initially generating a precursor CIS lesion. Basal cells are likely progenitors of CIS, muscle-invasive lesions and SCC, depending on the genetic background. Cancer stem cells are infamous for their inherent diminished susceptibility to treatment and for being generally difficult
to reach. They were suggested to contribute to therapeutic resistance through repopulation of residual tumours between chemotherapy cycles. Morphologically “normal” or dysplastic urothelium contains alterations found in tumour, pointing to spread of tumour cells or tumour development within the adjacent urothelium. Although some patients develop a true oligoclonal disease, tumours in the same patient are mostly related, showing evidence of subclonal evolution in different lesions. Genetic alterations pertinent to urothelial tumours are frequently found in the adjacent stromal cells. The importance of tumour milieu (surrounding stromal cells, extracellular matrix) in bladder cancer development is further underscored by its role in epithelial-to-mesenchymal transition (EMT). Cell invasivity and drug resistance then appear to increase in parallel with their angiogenetic and metastatic ability, thus contributing to tumourigenesis, tumour progression, and metastasis formation. Stromal cell types shown to contribute to bladder cancer progression include the mesenchymal stem cells and tumour-associated fibroblasts.
The immune system is another important determinant of tumour environment. The tumour-associated macrophages (TAMs) count in invasive cancers is significantly higher than in superficial cancers, and, correlates with TNM classification, tumour grade, vascular invasion, distant metastasis, response to BCG treatment and higher rates of cystectomy. Conversely, tumour infiltration by both Cytotoxic T-cells (CD68+) and T-cells in general (CD3+) promotes survival in patients with urothelial carcinoma.
The nature of immunological response induced by different molecular subtypes of urothelial carcinoma is independent of tumour stage and includes both TILs (Tumour-Infiltrating Lymphocytes) and TAMs. The strongest association with poor survival was observed for a high ratio between CD68+and CD3+. Susceptibility to specific drugs is more likely to be associated with the molecular stratification, rather than with pathologic classification.
To reduce the risk of bladder cancer recurrence and/or progression effectively, a treatment must ideally
a) Have an impact on cancer stem cells, harbouring the innermost tumour locations; b) Exert force on cellular and extracellular components on both sides of the basal membrane, to disrupt or transform the potentially disastrous interplay; and c) Modify the type of immunological response in the tumour vicinity to help offset cancer propagation.
The efficacy of Radiofrequency-Assisted chemotherapy instillation on drug diffusion was demonstrated with
Mitomycin C diffusing 6-fold higher using Synergo® RITE. MMC penetration of the bladder wall and cells can be explained by inter and intracellular drug-mobilising electric (“Foucault”) currents produced by the RF radiation and very efficient deep heat delivery. The same currents are also responsible for the cellular membrane "micro-poring" that enhance drug uptake, owing to ionic transfer. Tumour recurrence is substantially reduced following MMC via Synergo® RITE treatment compared with “conventional” MMC, or BCG instillation, and disease progression is reduced, even in patients presenting with CIS, G3 and patients failing BCG prior to Synergo® RITE treatment. As the available data on conductive heat-assisted MMC instillation indicates, it differs greatly from that of Synergo® RITE and it is apparent that the effect of Synergo® RITE cannot be explained by heat alone. Furthermore, it was demonstrated that liquid at 50-60°C irrigating the human bladder for up to two hours, did not destroy the urothelium (no denaturation of proteins took place) implying that the tissue was not effectively heated. A unique pattern of humoural and cell-mediated immunological response observed in patients treated with MMC via Synergo® RITE could also be a contributing factor in the apparently low recurrence and progression figures reported, even in high-risk patients. Early histological findings following treatment with MMC via Synergo® RITE show stromal behaviour post treatment. Intense vasodilatation and mainly lymphocytic infiltrate in peri-tumoural regions
were the hallmark of treatment with MMC via Synergo® RITE ˗ effects not seen with conventional or heated MMC instillation. Moreover, treatment with MMC via Synergo® RITE shows elevated urinary cytokine levels, with MCP-1 and IL-6 levels being significantly higher as well as increased macrophage-derived chemokine levels.

Medical Enterprises Group.
For more information and the full list of references, enter:

Monday, 30 June 2014

BAUS Annual Meeting in Liverpool 2014

BAUS Liverpool 2014

The Synergo booth at the recent BAUS meeting in Liverpool was well-attended by both British and overseas urologists. Over the past few years I have seen growing interest and also familiarity with the Synergo technology. The group from St. George’s, London, presented a 7-year study of 100 HR-NMIBC patients, treated with Synergo, showing a five-year survival comparable to that after cystectomy but with a lower morbidity.

A lively interest was also shown in our upcoming multicentric study in which a number of British Urology Departments will be taking part.

I would like to thank the organisers and BAUS members for making our participation such a memorable one.

Dr. Zvi Bar
Head of Clinical Department
Medical Enterprises Group

Dr. Zvi Bar, Head of Clinical Affairs, has been with MEL for two years. His main responsibilities are in the area of clinical training, seminars and research and development. Zvi joined MEL after a 35 year long career in Anesthesiology during which he held various posts including Head of Dept. of Anesthesiology and Chairman of The Committee ‎for Quality Assurance of The Ramat Marpe Hospital Group, as well as ‎Examiner in Anesthesiology for The Israel Medical Council‎.

Sunday, 25 May 2014

Erlangen Urology meeting 2014

The last urology meeting in Erlangen was well organized and the Synergo® RITE was well located! Few words in German for those who came to share experience and also just to express their interest. Below is Ms. Reich and her booth neighbour dressed in traditional Bavarian costume.

Es ist uns eine Freude, unsere neuen erfahrenen klinischen Fachleute im Team von Synergo® willkommen zu heißen, die uns bei der Ausdehnung unserer Aktivitäten mit urologischen Kliniken in Deutschland und Österreich helfen werden. Unser Ziel besteht darin, urologischen Kliniken eine Verbesserung von Ausbildung, Service und Unterstützung zu bieten. Wir erweitern unsere Aktivitäten mit der Synergo® Technologie, die überall auf der Welt zunehmend routinemäßig für die Behandlung von Patienten mit Blasenkrebs im mittleren Stadium oder mit hohem Risiko eingesetzt wird.

Frau Naama Reich, unsere medizinische Kontaktperson,  
40. Gemeinsamen Tagung der Bayerischen Urologenvereinigung sowie der Österreichischen Gesellschaft für Urologie und Andrologie zu treffen. Erlangen (Germany) 2014

Synergo® RITE (durch Radiofrequenz induzierter Thermo-Chemotherapie-Effekt) gegen nicht muskel-invasiven Blasenkrebs. 

Tuesday, 29 April 2014

Synergo at the EAU Annual Meeting 2014

EAU Annual Meeting, April 2014
Medical Enterprises thanks the urology colleagues, teams and organizers for the successful EAU congress in Stockholm this month. The congress was very successful and fruitful. Also many thanks for the new visitors who expressed their interest in the Synergo system.
2 poster sessions were presented at the EAU meeting this year by Mr. Issa and Mr. Nair from the UK. 

Synergo at the EAU 2014

Synergo at the EAU 2014

Challenging the gold standard: A comparison of long-term disease specific outcomes for high-risk non-muscle invasive bladder cancer treated with mitomycin hyperthermia and radical cystectomy:
A prospective single-centre review of 96 patients receiving Synergo MMC-HT and matched against 47 cases undergoing RC for High-Risk Non-Muscle Invasive Bladder Cancer. Charlson co-morbidity Index (CCI), and peri- and post-procedure complications were recorded in each group. Post operative pathology, recurrence and progression rates together with five-year overall and disease specific survival were evaluated.
The mean CCI score for patients receiving MMC-HT was significantly higher than RC group (6.1 vs 4.3). Significant complication rates classified as a Clavian-Dindo score of greater than 2, was significantly higher in the RC cohort (21 percent) compared to patients receiving MMC-HT (0 percent).
There were no deaths associated with MMC-HT treatment compared to a ninety-day mortality of four percent in those receiving RC.
Median follow-up was 36 months (3 to 88 months) for both cohorts. Disease specific survival at five years was observed at 85.2 and 74.6 percent in the MMC-HT and the RC cohorts respectively, whilst overall survival figures were 61.9 versus 68.4 percent.
Conclusions: "MMC-HT is both feasible and safe if offered to well selected patients. It provides durable long-term outcomes compared to RC for HR-NMIBC.....there is a clear advantage in complication rates favouring MMC-HT over RC without a significant difference in disease specific or overall survival."

The efficacy and safety of mitomycin-C hyperthermia in the treatment of high risk (HR) non-muscle invasive bladder cancer (NMIBC) in a single regional centre.
A report on seven year experience of MMC-HT, and aim to establish whether it is efficacious in this high risk cohort of patients.
100 patients with HR NMIBC were treated with MMC-HT (3 patients did not complete induction regimen due to side effects,  1 patient developed clinical metastases during the first two weeks of induction course).  96 patients completed induction treatment and had cystoscopy and biopsy at 3 months.  Of these 96 patients, 84 had failed BCG or were intolerant to it.  Patients were given an induction regimen with weekly treatments for 6-8 weeks with MMC-H on an outpatient basis with the Synergo® system SB-TS 101.
Median follow up was 34 months (3 to 88 months). 72% of patients (69/96) had complete response at 3 months, 10% had partial response (10/96) and 18% (17/96) had recurrence. Twenty patients had radical cystectomy.  Eighteen patients had organ confined disease and two patients had T3 disease at histology.  Only one patient developed recurrence of disease after cystectomy. No patients suffered a Clavien-Dindo Complication above 2.
Conclusions: "MMC-HT has comparable five year survival to radical cystectomy in the treatment of high risk superficial bladder cancer after BCG failure. It is well tolerated and can be delivered effectively by a regional centre. In those patients who are medically fit, cystectomy is still a potentially curative option for those patients who fail MMC-HT."